1 not yet recruiting, 1 recruiting, 1 withdrawn. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Follicular Lymphoma ( FL): new trials by email Literature Review of Follicular Lymphoma ( FL) trials Research Report on Follicular Lymphoma ( FL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma Orelabrutinib, obinutuzumab, Lenalidomide - Follicular Lymphoma ( FL) | Phase 3 | Not yet recruiting | Ruijin Hospital | 652 | 2026-07-01 | 2026-07-22 |
| NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) Talikabtagene Autoleucel - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | Health Institutes of Turkey | 40 | 2025-09-11 | 2026-03-30 |
| To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) parsaclisib, rituximab, obinutuzumab - Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) | Phase 3 | Withdrawn | Incyte Corporation | 2022-12-30 | 2022-07-18 |
Lymphoma, Follicular (3) · Recurrence (2) · Burkitt Lymphoma (1) · Cytokine Release Syndrome (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Disease Attributes (2) · Lymphoma, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · DNA Virus Infections (1) · Epstein-Barr Virus Infections (1)
obinutuzumab (2) · Bendamustine Hydrochloride (1) · Cyclophosphamide (1) · Doxorubicin (1) · Lenalidomide (1) · Prednisone (1) · Rituximab (1) · Vincristine (1) · orelabrutinib (1) · parsaclisib (1)
Health Institutes of Turkey (1) · Incyte Corporation (1) · Ruijin Hospital (1)
China (1) · Turkey (Türkiye) (1)